CD274 and neoplasm: Among the PE and PA groups, the median OS was 28.6 vs. 21.3 months for a PD-L1 CPS ≥50 (p = 0.001), 26.6 vs. 19.4 months for a CPS ≥20 (p = 0.001), and 21.4 vs. 16.8 months for a CPS ≥1 (p = 0.001); the benefit from PE therapy seemed more evident for higher PD-L1 expression in tumor cells (indicating an anti-tumor immune response).